Cushing's Disease Clinical Trials

34 clinical trials for Cushing's Disease across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Trial of Lu AG13909 in Adult Participants With Cushing's Disease — RECRUITING · PHASE2
• DDAVP for Pituitary Adenoma — RECRUITING · NA
• Collecting Information About Treatment Results for Patients With Cushing's Syndrome — RECRUITING
• A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease. — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease — TERMINATED · PHASE2
• A DOUBLE-BLIND, RANDOMISED, 30-WEEK PLACEBO-CONTROLLED PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF OSILODROSTAT IN PATIENTS WITH HYPERTENSION CAUSED BY HYPERCORTISOLAEMIA DUE TO CUSHING’S SYNDROME — NOT_YET_RECRUITING · PHASE4
• A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease — TERMINATED · PHASE2
• Cushing's Disease Complications — COMPLETED
• Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease — COMPLETED · NA
• Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus®-21) — TERMINATED · PHASE2
• Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease — COMPLETED · NA
• Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease — WITHDRAWN · PHASE2
• A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease — OTHER · PHASE2
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies — COMPLETED · PHASE4
• CONTINUATION OF AN OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS LONG TERM SAFETY IN CANADIAN PATIENTS WITH ENDOGENOUS CUSHING¿S SYNDROME WHO HAVE COMPLETED PRIOR RECORDATI-SPONSORED OSILODROSTAT (LCI699) STUDY LCI699C2X01B — NOT_YET_RECRUITING
• Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease — COMPLETED · PHASE3
• Long-term Cardiovascular Risk in Cured Cushing's Patients — TERMINATED
• Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) — TERMINATED · PHASE2
• Seoul National University Pituitary Disease Cohort Study — OTHER
• GLUCOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CUSHING SYNDROME (GRACE): A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF RELACORILANT — COMPLETED · PHASE3
• Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly — COMPLETED · PHASE4
• AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO ASSESS LONG TERM SAFETY IN PATIENTS WITH ENDOGENOUS CUSHING¿S SUNDROME WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED OSILODROSTAT (LCI699) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH OSILODROSTAT. — COMPLETED
• An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. — COMPLETED · PHASE3
• Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease — COMPLETED · PHASE3
• A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 48 WEEK STUDY WITH AN INITIAL 12 WEEK PLACEBO-CONTROLLED PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF OSILODROSTAT IN PATIENTS WITH CUSHING¿S DISEASE — COMPLETED · PHASE3
• Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease — COMPLETED · PHASE3
• Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease — OTHER · PHASE2
• AN OPEN LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF COR-003 (2S, 4R- KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME — COMPLETED
• Mifepristone in Children With Refractory Cushing's Disease — WITHDRAWN · PHASE3
• A PHASE III, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK, SINGLE-ARM, OPEN-LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS WITH CUSHING'S DISEASE — COMPLETED · PHASE3
• Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome — COMPLETED · PHASE3
• AN OPEN LABEL, MULTI-CENTER PASIREOTIDE ROLL-OVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS-SPONSORED PASIREOTIDE STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED PASIREOTIDE TREATMENT — COMPLETED
• Preoperative Bexarotene Treatment for Cushing's Disease — OTHER · PHASE1
• Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor — COMPLETED · PHASE3

Refine this search